Single-center cohort finds MIRT most sensitive at predicting malnutrition or low Fat-Free Mass Index within six months in patients in remission with IBD; SaskIBD-NR shows the highest accuracy for GLIM-defined malnutrition and for low Fat-Free Mass Index.
The addition of durvalumab and bevacizumab to transarterial chemoembolization may improve progression-free survival in unresectable hepatocellular carcinoma.
The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.
Study reveals hospital variation in SGLT2i prescriptions, with only 11 of 518 hospitals (2.1%) achieving ≥50% prescription rates while 232 hospitals (44.8%) prescribed to fewer than 10% of eligible heart failure patients, highlighting an implementation gap in evidence-based therapy.